Elanco Animal Health Incorporated Operating Expenses
Elanco Animal Health Incorporated (ELAN) reported Operating Expenses of $486.80 million for the 3-month period ending 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2021-03-01
- Elanco Animal Health Incorporated operating expenses for the quarter ending 2020-12-31 was $486.80M, a 92.26% increase year-over-year.
- Elanco Animal Health Incorporated operating expenses for the quarter ending 2019-12-31 was $253.20M, a 2.84% increase year-over-year.
- Elanco Animal Health Incorporated operating expenses for the quarter ending 2019-09-30 was $262.20M, a 10.21% increase year-over-year.
- Elanco Animal Health Incorporated operating expenses for the quarter ending 2019-06-30 was $269.70M, a 6.81% increase year-over-year.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2020-12-31 | $486.80M 10-K · filed 2021-03-01 | |||
| 2019-12-31 | $253.20M 10-K · filed 2021-03-01 | $515.40M derived: sum of 2 quarters · filed 2021-03-01 | $785.10M derived: sum of 3 quarters · filed 2021-03-01 | $1.03B derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-09-30 | $262.20M 10-K · filed 2020-02-28 | $531.90M derived: sum of 2 quarters · filed 2020-02-28 | $777.10M derived: sum of 3 quarters · filed 2020-02-28 | $1.02B derived: sum of 4 quarters · filed 2020-02-28 |
| 2019-06-30 | $269.70M 10-K · filed 2020-02-28 | $514.90M derived: sum of 2 quarters · filed 2020-02-28 | $761.10M derived: sum of 3 quarters · filed 2020-02-28 | $999.00M derived: sum of 4 quarters · filed 2020-02-28 |
| 2019-03-31 | $245.20M 10-K · filed 2020-02-28 | $491.40M derived: sum of 2 quarters · filed 2020-02-28 | $729.30M derived: sum of 3 quarters · filed 2020-02-28 | $981.80M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-12-31 | $246.20M 10-K · filed 2020-02-28 | $484.10M derived: sum of 2 quarters · filed 2020-02-28 | $736.60M derived: sum of 3 quarters · filed 2020-02-28 | $981.80M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-09-30 | $237.90M 10-K · filed 2020-02-28 | $490.40M derived: sum of 2 quarters · filed 2020-02-28 | $735.60M derived: sum of 3 quarters · filed 2020-02-28 | $994.40M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-06-30 | $252.50M 10-K · filed 2020-02-28 | $497.70M derived: sum of 2 quarters · filed 2020-02-28 | $756.50M derived: sum of 3 quarters · filed 2020-02-28 | $1.01B derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-03-31 | $245.20M 10-K · filed 2020-02-28 | $504.00M derived: sum of 2 quarters · filed 2020-02-28 | $760.60M derived: sum of 3 quarters · filed 2020-02-28 | $1.02B derived: sum of 4 quarters · filed 2020-02-28 |
| 2017-12-31 | $258.80M 10-K · filed 2019-02-20 | $515.40M derived: sum of 2 quarters · filed 2019-02-20 | $773.20M derived: sum of 3 quarters · filed 2019-02-20 | $1.03B derived: sum of 4 quarters · filed 2019-02-20 |
| 2017-09-30 | $256.60M 10-K · filed 2019-02-20 | $514.40M derived: sum of 2 quarters · filed 2019-02-20 | $772.70M derived: sum of 3 quarters · filed 2019-02-20 | |
| 2017-06-30 | $257.80M 10-K · filed 2019-02-20 | $516.10M derived: sum of 2 quarters · filed 2019-02-20 | ||
| 2017-03-31 | $258.30M 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |